What is NFlection Therapeutics?
NFlection Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted topical therapies for rare dermatological conditions. The company's pipeline includes first-in-class MEK inhibitors designed to treat RAS-mediated disorders, such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks. Their innovative approach aims to address significant unmet needs in patient populations suffering from these challenging conditions.
How much funding has NFlection Therapeutics raised?
NFlection Therapeutics has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2020): $20M with participation from F-Prime Capital and venBio Partners
Key Investors in NFlection Therapeutics
F-Prime Capital
F-Prime Capital is a venture capital firm established in 2002, specializing in investments within the healthcare and technology sectors. They provide a team of experienced investors, engineers, doctors, and scientists to support their portfolio companies.
venBio Partners
venBio Partners is a life sciences investment firm founded in 2011, focusing on developing innovative medicines and technologies to address unmet medical needs. They partner with industry leaders and aim to position portfolio companies for success through strategic guidance and capital.
What's next for NFlection Therapeutics?
With the recent major strategic investment, NFlection Therapeutics is poised to accelerate its clinical development programs and further its research into MEK inhibitors. This capital infusion is expected to support the advancement of their pipeline candidates through critical clinical trial phases, potentially bringing new therapeutic options to patients with rare dermatological diseases. The company's focus on addressing the aberrant activation of the Ras/Raf/MEK/ERK pathway positions it at the forefront of targeted therapy development in this specialized field.
See full NFlection Therapeutics company page
